Jim Simons’s Tarsus Pharmaceuticals TARS Stock Holding History

Jim Simons’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.15M	Buy	73,400 +9,300	+15%	+$650K	0.01%	1366
2025 Q4	$5.25M	Buy	64,100 +22,500	+54%	+$1.68M	0.01%	1275
2025 Q3	$2.47M	Buy	+41,600	New	+$2.05M	﹤0.01%	1930
2023 Q4	–	Sell	-106,900	Closed	-$1.9M	–	4124
2023 Q3	$1.9M	Sell	106,900 -7,600	-7%	-$134K	﹤0.01%	1900
2023 Q2	$2.07M	Buy	114,500 +40,500	+55%	+$644K	﹤0.01%	1975
2023 Q1	$930K	Buy	74,000 +8,400	+13%	+$123K	﹤0.01%	2524
2022 Q4	$962K	Sell	65,600 -3,900	-6%	-$64.5K	﹤0.01%	2557
2022 Q3	$1.19M	Buy	69,500 +9,200	+15%	+$146K	﹤0.01%	2390
2022 Q2	$880K	Buy	+60,300	New	+$905K	﹤0.01%	2798

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jim Simons's TARS Position: Q1 2026 in Review

Jim Simons increased its Tarsus Pharmaceuticals (TARS) stake by 15% in Q1 2026, buying an estimated $650K and bringing the position to 73,400 shares worth $5.15M. The position accounts for 0.01% of the portfolio, ranked #1366.

Jim Simons first reported a position in TARS in Q2 2022 and has held it in 9 quarters since. The position peaked at $5.25M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Jim Simons held 73,400 shares of Tarsus Pharmaceuticals worth $5.15M as of Q1 2026.
Jim Simons bought 9,300 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $650K.
Tarsus Pharmaceuticals made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1366 holding.
Jim Simons first reported a position in Tarsus Pharmaceuticals in Q2 2022 and has held it in 9 quarters since.
Jim Simons's Tarsus Pharmaceuticals position peaked at $5.25M in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.